Example Hypotheses for Pharmaceutical Drug Discovery Validation

Below are several structured, actionable hypotheses that pharmaceutical scientists could validate using your solution, which leverages scoring from public medical research articles. Each hypothesis targets different phases of drug discovery and is designed for practical, evidence-driven assessment.

1. Target Identification & Disease Association

Hypothesis:
Inhibition of the NLRP3 inflammasome reduces neuroinflammation and slows the progression of Alzheimer's disease.

This hypothesis can be validated by scoring evidence linking NLRP3 targeting to neuroinflammatory markers, tau/Aβ pathology reduction, and clinical symptoms in both preclinical and clinical studies.

2. Drug Repurposing and New Indications

Hypothesis:
SGLT2 inhibitors, originally developed for type 2 diabetes, improve renal outcomes in non-diabetic chronic kidney disease patients.

Evidence scoring would include effectiveness, safety, and mechanistic studies from clinical trials and meta-analyses in populations without diabetes.

3. Novel Mechanism Exploration

Hypothesis:
Small molecule agonists of TrkB receptors promote neurogenesis and functional recovery after ischemic stroke.

Validation involves scoring preclinical studies demonstrating neurogenic effects, pathway activation, and functional improvements, as well as any early-phase clinical trial data.

4. Predictive Biomarker Identification

Hypothesis:
Expression levels of PD-L1 in tumor tissue predict response to anti-PD-1 immunotherapy in advanced non-small cell lung cancer.

Scoring will cover correlation strength, reproducibility, and clinical outcome details from oncology trials using immunotherapy agents.

5. Candidate Safety Profiling

Hypothesis:
Long-term administration of GLP-1 receptor agonists does not increase incidence of pancreatitis in obese patients with type 2 diabetes.

Validation would analyze adverse event reporting, epidemiological studies, and controlled trial safety profiles.

6. Combination Therapy Synergy

Hypothesis:
Combination therapy of BRAF inhibitors with MEK inhibitors yields superior progression-free survival compared to BRAF mono-therapy in BRAF-mutated melanoma patients.

Relevant validation evidence would include comparative clinical trial data, survival analysis, and mechanism of synergy.

7. Genetic Variant as Drug Target

Hypothesis:
Loss-of-function mutations in PCSK9 are associated with reduced LDL cholesterol and lower cardiovascular risk, making PCSK9 a viable therapeutic target.

Scores would derive from genetic studies, functional assays, and clinical intervention efficacy.

These example hypotheses are drawn from current trends and prevailing questions in pharmacological research. Your system can provide scientists with quantitative, evidence-based validation by aggregating and structuring scores from relevant published studies, thus accelerating decision-making in drug discovery and development.

50 Diverse Drug Discovery Hypotheses for Validation

Cancer and Immunotherapy (10 hypotheses)

1. NLRP3 inflammasome inhibition reduces tumor-associated macrophage M2 polarization and enhances anti-PD-1 efficacy in triple-negative breast cancer [1] [2]

2. Combination of bispecific antibodies targeting CD3 and tumor-associated antigens with CAR-T cells improves solid tumor penetration and persistence [3] [2]

3. ITPRIPL1 checkpoint inhibition enhances NK cell cytotoxicity against hepatocellular carcinoma [4] [1]

4. CRISPR-mediated upregulation of MHC class I expression in tumor cells overcomes immune evasion in microsatellite-stable colorectal cancer [4]

5. Senolytic drugs targeting senescent cells in the tumor microenvironment improve CAR-T cell function in aged patients [5] [2]

6. Anti-VEGFR1/FLT1 antibodies combined with anti-angiogenic therapy restore blood-brain barrier function in glioblastoma [6]

7. Targeting CD274 (PD-L1) overexpression through CRISPR activation screening identifies resistance mechanisms to checkpoint inhibitors [4]

8. Engineered T cells with enhanced IL-2 and IFN-γ production show superior anti-tumor activity in pancreatic adenocarcinoma [4]

9. Dual targeting of MCL1 and JUNB pathways overcomes cytotoxic T-cell resistance in melanoma [4]

10. Combination of oncolytic viruses with immune checkpoint inhibitors enhances systemic anti-tumor immunity [2] [3]

Neurodegeneration and CNS Disorders (8 hypotheses)

11. GPNMB targeting reduces alpha-synuclein aggregation and neuroinflammation in Parkinson's disease [7] [8]

12. Modulation of BIN1 protein levels improves tau clearance and synaptic function in Alzheimer's disease [7]

13. SARM1 inhibition prevents axonal degeneration and slows disease progression in amyotrophic lateral sclerosis [7]

14. Combination therapy targeting both NMDA receptors and voltage-gated calcium channels provides neuroprotection in Huntington's disease [8]

15. MAPK1 inhibition reduces neuroinflammation and restores blood-brain barrier integrity in multiple sclerosis [6]

16. GRN (granulin) replacement therapy slows cognitive decline in frontotemporal dementia [7]

17. Targeting CD38 in brain microglia reduces neuroinflammation and improves motor function in Parkinson's disease [7]

18. FGFR1 activation promotes neurogenesis and functional recovery after traumatic brain injury [6]

Metabolic and Endocrine Diseases (6 hypotheses)

19. GLP-1 receptor agonists combined with SGLT2 inhibitors provide superior glycemic control and cardiovascular protection in type 2 diabetes [9] [10]

20. Targeting branched-chain amino acid metabolism pathways prevents insulin resistance development [9]

21. Beta-sitosterol supplementation improves insulin sensitivity and reduces inflammation in metabolic syndrome [11]

22. Adenosine receptor modulation enhances glucose uptake and improves metabolic profiles in diabetes [11]

23. Choline supplementation prevents hepatic steatosis and improves lipid metabolism in non-alcoholic fatty liver disease [11]

24. Scopoletin-derived compounds activate AMPK pathway and improve metabolic function in obesity [11]

Autoimmune and Inflammatory Diseases (8 hypotheses)

25. BTK inhibition provides superior efficacy compared to JAK inhibition in rheumatoid arthritis with reduced cardiovascular risk [12] [13]

26. IL-33 blockade prevents tissue fibrosis and organ damage in systemic sclerosis [12]

27. STAT3 selective inhibition reduces inflammation while preserving protective immunity in inflammatory bowel disease [14]

28. Telitacicept (BAFF/APRIL inhibition) improves glandular function and reduces systemic manifestations in Sjögren's syndrome [15]

29. Engineered CAR-T cells targeting CD19+ autoreactive B cells induce sustained remission in systemic lupus erythematosus [16]

30. Dazodalibep (CD40L antagonist) prevents organ damage progression in multiple autoimmune diseases [15]

31. Iscalimab (anti-CD40) reduces disease activity and autoantibody production in myasthenia gravis [15]

32. Combination of IL-23 and IL-17 inhibition provides superior clinical outcomes in psoriatic arthritis [17]

Infectious Diseases (6 hypotheses)

33. Engineered bacteriophages targeting carbapenem-resistant Enterobacteriaceae restore antibiotic susceptibility through plasmid curing [18]

34. Host-targeted antiviral therapies inhibiting human protein kinases reduce viral replication across multiple RNA virus families [19]

35. CRISPR-based antimicrobials selectively eliminate methicillin-resistant Staphylococcus aureus without affecting commensal bacteria [18]

36. Combination of rezafungin with immunomodulatory agents improves outcomes in invasive aspergillosis [18]

37. Broad-spectrum antivirals targeting viral RNA polymerase conserved domains prevent pandemic outbreaks [20]

38. Phage-antibiotic synergy therapy overcomes biofilm-mediated resistance in chronic wound infections [18]

Rare and Orphan Diseases (5 hypotheses)

39. Gene therapy using adeno-associated virus vectors corrects metabolic defects in Pompe disease [21]

40. Small molecule chaperones restore protein folding and function in lysosomal storage disorders [21]

41. Antisense oligonucleotides targeting splicing mutations provide therapeutic benefit in spinal muscular atrophy variants [3]

42. CRISPR base editing corrects point mutations causing sickle cell disease without off-target effects [21]

43. Substrate reduction therapy combined with enzyme replacement improves clinical outcomes in Gaucher disease [21]

Precision Medicine and Targeted Therapy (4 hypotheses)

44. Tumor organoids predict patient response to immunotherapy combinations better than standard biomarkers [22] [23]

45. Liquid biopsy-guided treatment selection improves progression-free survival in metastatic cancer [22]

46. Pharmacogenomic testing reduces adverse drug reactions by 40% in cardiovascular disease management [24]

47. AI-guided drug repurposing identifies new indications for approved medications with 80% accuracy [23]

Microbiome-Based Therapeutics (3 hypotheses)

48. Engineered probiotics producing therapeutic proteins treat inflammatory bowel disease more effectively than systemic administration [25] [26]

49. Fecal microbiota transplantation combined with immune checkpoint inhibitors improves response rates in melanoma [27]

50. Selective gut microbiome modulation reduces drug metabolism and improves bioavailability of oral cancer therapies [28] [26]

These hypotheses span diverse therapeutic areas and mechanisms, incorporating current trends in drug discovery including AI/ML applications, CRISPR technology, precision medicine approaches, novel drug modalities like PROTACs and bispecific antibodies, microbiome therapeutics, and regenerative medicine strategies. Each hypothesis is designed to be specific, testable, and suitable for validation through structured scoring of public medical research literature.

⁂

1. https://www.sciencedirect.com/science/article/pii/S2950347725000180
2. https://ijmio.com/emerging-strategies-in-cancer-immunotherapy-expanding-horizons-and-future-perspectives/
3. https://www.bcg.com/publications/2025/emerging-new-drug-modalities
4. https://www.nature.com/articles/s41388-025-03273-8
5. https://www.quanticate.com/blog/insights-into-the-therapeutic-areas-in-clinical-research
6. https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2021.639160/full
7. https://pubmed.ncbi.nlm.nih.gov/36759259/
8. https://pmc.ncbi.nlm.nih.gov/articles/PMC3637880/
9. https://pmc.ncbi.nlm.nih.gov/articles/PMC10543515/
10. https://drughunter.com/category/metabolic-disease
11. https://www.nature.com/articles/s41598-022-20752-0
12. https://www.nature.com/articles/d41573-025-00061-7
13. https://www.tandfonline.com/doi/full/10.1080/08916934.2024.2330392
14. https://pubmed.ncbi.nlm.nih.gov/39180944/
15. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1249500/full
16. https://kyvernatx.com/platform-pipeline/opportunity/
17. https://www.nature.com/articles/s41392-024-01952-8
18. https://www.contagionlive.com/view/advancements-in-targeted-therapies-for-infectious-diseases
19. https://pmc.ncbi.nlm.nih.gov/articles/PMC8964018/
20. https://pmc.ncbi.nlm.nih.gov/articles/PMC11258021/
21. https://pmc.ncbi.nlm.nih.gov/articles/PMC5662129/
22. https://pmc.ncbi.nlm.nih.gov/articles/PMC8691416/
23. https://www.tandfonline.com/doi/full/10.1080/23808993.2024.2393089
24. https://pmc.ncbi.nlm.nih.gov/articles/PMC6287751/
25. https://pubmed.ncbi.nlm.nih.gov/38307852/
26. https://pubs.acs.org/doi/10.1021/acs.chemrestox.9b00333
27. https://www.nature.com/articles/s41573-025-01211-7
28. https://www.nature.com/articles/s41467-023-39264-0

29. https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-trends-in-r-and-d-2025
30. https://www.fda.gov/files/drugs/published/new-drug-therapy-2025-annual-report.pdf
31. https://www.pelagobio.com/cetsa-drug-discovery-resources/blog/drug-discovery-trends-2025/
32. https://www.nature.com/articles/s41392-024-01911-3
33. https://www.sciencedirect.com/science/article/pii/S2949866X24001084
34. https://pmc.ncbi.nlm.nih.gov/articles/PMC11334170/
35. https://www.sciencedirect.com/science/article/abs/pii/S0223523425000066
36. https://www.ispor.org/heor-resources/presentations-database/presentation-cti/ispor-2025/poster-session-4/trends-in-the-global-drug-development-pipeline-2024
37. https://www.sciencedirect.com/science/article/pii/S1359644624000679
38. https://globalresearchonline.net/ijpsrr/v85-2/17.pdf
39. https://www.cas.org/resources/cas-insights/2025-drug-discovery-trends
40. https://www.discoveryontarget.com/target-identification-strategies
41. https://drughunter.com/articles/2024-novel-small-molecule-fda-drug-approvals
42. https://www.coherentmarketinsights.com/industry-reports/drug-discovery-platforms-market
43. https://pubs.acs.org/doi/10.1021/acs.jmedchem.4c00568
44. https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bph.17458
45. https://www.towardshealthcare.com/insights/drug-discovery-saas-platforms-market-sizing
46. https://www.gsk.com/en-gb/innovation/therapeutic-areas/
47. https://pubmed.ncbi.nlm.nih.gov/37979454/
48. https://www.discoveryontarget.com/neurodegeneration-targets
49. https://pubmed.ncbi.nlm.nih.gov/39940772/
50. https://www.authorea.com/users/570887/articles/1241490-unlocking-new-frontiers-novel-immune-targets-for-next-gen-cancer-immunotherapy
51. https://www.nature.com/articles/s41591-025-03834-0
52. https://www.drugtargetreview.com/article/35746/metabolomics-drug-biomarker-discovery/
53. https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bph.16078
54. https://academic.oup.com/nar/article/53/D1/D1467/7917960
55. https://www.cancerresearch.org/media-room/the-2024-impact-report-of-the-cancer-research-institute
56. https://www.sciencedirect.com/science/article/pii/S1043661824003402
57. https://pubmed.ncbi.nlm.nih.gov/PMC10943205
58. https://www.sciencedirect.com/science/article/pii/S1359644625000595
59. https://www.frontiersin.org/research-topics/17270/novel-therapeutic-interventions-against-infectious-diseases-covid-19/magazine
60. https://pubs.acs.org/doi/10.1021/acs.jcim.4c01966
61. https://gcgh.grandchallenges.org/grant/novel-therapeutics-boost-innate-immunity-treat-infectious-diseases
62. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1441807/full

63. https://www.youtube.com/watch?v=4tSxrZFBaBk
64. https://www.fda.gov/patients/rare-diseases-fda
65. https://ascpt.onlinelibrary.wiley.com/doi/10.1111/cts.70215
66. https://www.frontiersin.org/research-topics/29606/novel-and-alternative-therapeutic-agents-for-controlling-infectious-diseases-of-poultry/magazine
67. https://pmc.ncbi.nlm.nih.gov/articles/PMC4109573/
68. https://www.sciencedirect.com/science/article/pii/S2950523224000010
69. https://www.pnas.org/doi/10.1073/pnas.1508520112
70. https://www.fda.gov/medical-devices/in-vitro-diagnostics/precision-medicine
71. https://www.sciencedirect.com/topics/agricultural-and-biological-sciences/regenerative-medicine
72. https://www.sciencedirect.com/science/article/pii/S0959440X23000416
73. https://pmc.ncbi.nlm.nih.gov/articles/PMC4980802/
74. https://www.nature.com/articles/s41392-022-01134-4
75. https://www.mdanderson.org/treatment-options/targeted-therapy.html
76. https://www.ukri.org/what-we-do/browse-our-areas-of-investment-and-support/regenerative-medicine/
77. https://www.biocompare.com/Editorial-Articles/569434-Importance-Microbiome-Drug-Discovery/
78. https://www.efpia.eu/about-medicines/development-of-medicines/precision-medicine/
79. https://www.mayo.edu/research/clinical-trials/tests-procedures/regenerative-medicine-therapy